Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease

Background/AimsThis was a Phase 2 study (NCT02015793) to evaluate the pharmacokinetics, safety, and efficacy of adalimumab in Chinese patients with Crohn's disease (CD).MethodsThirty, adult Chinese patients with CD (CD Activity Index [CDAI] 220–450; high-sensitivity [hs]-C-reactive protein [CRP...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:Intestinal Research
المؤلفون الرئيسيون: Kai-Chun Wu, Zhi Hua Ran, Xiang Gao, Minhu Chen, Jie Zhong, Jian-Qiu Sheng, Michael A Kamm, Simon Travis, Kori Wallace, Nael M Mostafa, Marisa Shapiro, Yao Li, Roopal B Thakkar, Anne M Robinson
التنسيق: مقال
اللغة:الإنجليزية
منشور في: Korean Association for the Study of Intestinal Diseases 2016-04-01
الموضوعات:
Crohn disease
Anti-tumor necrosis factor
Adalimumab
الوصول للمادة أونلاين:http://www.irjournal.org/upload/pdf/ir-14-152.pdf

الانترنت

http://www.irjournal.org/upload/pdf/ir-14-152.pdf

مواد مشابهة